

Development of a novel intrauterine levonorgestrel-releasing system for treatment and contraception: initial clinical experience

D. Janssens (1), D. Wildemeersch(2), M. Thiery(3)

(1) Gynaecologische Dienst, Turnhout, Belgium

(2) Contrel Research, Techno loy Park Zwijnaarde, Ghent, Belgium

(3) Department of Obs & Gyn, University Hospital, Ghent, Belgium

FibroPlant, a levonorgestrel (LNG)-releasing intrauterine system (IUS) has been clinically developed since 1997 for endometrial protection during estrogen replacement therapy, for treatment of menorrhagia in women with normal uteri or with uterine fibroids, for treatment of endometrial hyperplasia, for alleviating dysmenorrhoea and for contraception.

The frameless drug delivery support of this hormone-releasing IUS reduces the size of the foreign body, thereby maximizing tolerance and continuation of use, while simultaneously providing for a maximum duration of action.

Results of preliminary studies in 350 patients confirm the promising nature of this drug delivery system. The low dose of the LNG released (14 microgram/day) accounts for the low hormonal side-effect rate and virtual absence of amenorrhoea in premenopausal women.